Ribolia Presents Multiple Cardiovascular Drug Clinical Data at ESC 2025 and Files for IPO

At the 2025 European Society of Cardiology Congress (ESC 2025) held recently in Madrid, Spain, Suzhou Ribo Life Science Co., Ltd. ("Ribo Life Science" or "the Company") and its international R&D center (Ribocure) jointly announced four significant clinical research achievements, highlighting the company's important progress in siRNA innovative therapies in the cardiovascular field.

Ribo Life Science Announces Phase I Clinical Trial Results of RBD5044 Targeting ApoC3

Ribo Life Science also announced the results of a clinical observational study exploring the role of ApoC3 in 197 high-risk patients with acute coronary syndrome after receiving optimal standard treatment. The results were as expected: elevated ApoC3 levels were closely associated with adverse lipid profiles; more importantly, ApoC3 levels showed a significant positive correlation with pro-inflammatory and pro-fibrotic biomarkers. During the 5.5-year follow-up period, patients with high ApoC3 levels faced more than double the risk of major adverse cardiovascular events (MACE). This finding, together with the results from interventional trials, confirms the critical role of ApoC3 in triglyceride-rich lipoprotein metabolism and its potential role in systemic inflammation, suggesting that silencing this target could bring clinical benefits to relevant populations.

Ribo Life Science announced the Phase I data of the RBD7022 project targeting PCSK9, which has entered Phase II clinical trials and completed the enrollment of all subjects. The study included healthy volunteers and patients with hypercholesterolemia who were either receiving or not receiving statin therapy. Results showed that using PCSK9 levels as a target biomarker, the addition of RBD7022 in patients with or without statin treatment resulted in a maximum reduction of up to 75%, maintaining this inhibition level at the 6-month follow-up. Meanwhile, the treatment was well-tolerated. Current results further support the continued development of this project as a key therapy for lowering low-density lipoprotein cholesterol (LDL-c).

Finally, Ribo Life Science presented clinical observational study results at the conference to support its FXI-targeting RBD4059 project. The RBD4059 project is the world’s first siRNA therapy targeting FXI to enter clinical trials and is currently the most advanced, now in Phase II clinical studies. The reported observational study conducted an in-depth phenotypic analysis of high-risk coronary artery disease patients undergoing percutaneous coronary intervention. The results showed a correlation between elevated FXI levels and increased endothelial activation biomarkers, as well as impaired endothelial function during the follow-up period after an event. These findings suggest that silencing FXI may not only provide powerful antithrombotic effects and minimize bleeding risks but also potentially offer other significant benefits to patients.